Abstract
The absence of a graft-versus-malignancy (GVM) effect may be responsible for the higher relapse rate seen after autologous hematopoietic cell transplantation (auto-HCT) compared with allogeneic hematopoietic cell transplantation (allo-HCT). Acute GVHD developing after allo-HCT, however, is associated with significant morbidity and mortality. An autoimmune syndrome similar to acute GVHD has been reported to occur after auto-HCT and has been termed the ‘auto-aggression’ syndrome or autologous GVHD (auto-GVHD). Auto-GVHD tends to be milder than classical GVHD, most commonly involves the skin (rarely the gastrointestinal tract, liver or both) and often is self-limited. Auto-GVHD has been reported to occur both spontaneously and in subjects receiving post transplant immune modulation with CsA, IFN-γ or the combination. The development of auto-GVHD depends upon the derangement of self tolerance either through administration of post transplant CsA, depletion of regulatory T cells following the preparative chemoradiotherapy or both. Self-reactive CD8+ T cells paradoxically are able to recognize a self peptide antigen presented by MHC class II molecules and appear to mediate the syndrome. Many clinical trials have been performed using CsA with or without IFN-γ in an attempt to induce auto-GVHD. While many patients do indeed develop the syndrome, any associated anti-tumor effect remains questionable to date. New strategies to exploit auto-GVHD and enhance a GVM effect such as through the depletion of regulatory T cells or through use of newer immunomodulatory agents may improve the efficacy of auto-HCT.
Similar content being viewed by others
References
Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.
Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED . Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533.
Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B . Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196–1198.
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.
Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801–813.
Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406–413.
Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071.
Hood AF, Vogelsang GB, Black LP, Farmer ER, Santos GW . Acute graft-vs-host disease. Development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123: 745–750.
Jones RJ, Vogelsang GB, Hess AD, Farmer ER, Mann RB, Geller RB et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754–757.
Holmberg L, Kikuchi K, Gooley TA, Adams KM, Hockenbery DM, Flowers ME et al. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2006; 12: 226–234.
Saunders MD, Shulman HM, Murakami CS, Chauncey TR, Bensinger WL, McDonald GB . Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. Am J Surg Pathol 2000; 24: 1004–1008.
Sica S, Chiusolo P, Salutari P, Piccirillo N, Laurenti L, Sora F et al. Autologous graft-versus-host disease after CD34+-purified autologous peripheral blood progenitor cell transplantation. J Hematother Stem Cell Res 2000; 9: 375–379.
Baron F, Gothot A, Salmon JP, Hermanne JP, Pierard GE, Fillet G et al. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. Br J Haematol 2000; 111: 745–753.
Glazier A, Tutschka PJ, Farmer ER, Santos GW . Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med 1983; 158: 1–8.
Hess AD, Horwitz L, Beschorner WE, Santos GW . Development of graft-vs-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 1985; 161: 718–730.
Jenkins MK, Schwartz RH, Pardoll DM . Effects of cyclosporine A on T cell development and clonal deletion. Science 1988; 241: 1655–1658.
Gao EK, Lo D, Cheney R, Kanagawa O, Sprent J . Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988; 336: 176–179.
Miura Y, Ueda M, Takami A, Shiobara S, Nakao S, Hess AD . Enhancement of cyclosporin A-induced autologous graft-versus-host disease after peripheral blood stem cell transplantation by utilizing selected CD34(+) cells. Bone Marrow Transplant 2003; 32: 785–790.
Hess AD . Autologous graft-versus-host disease. J Hematother Stem Cell Res 2000; 9: 297.
Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K et al. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 1997; 15: 667–673.
Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993; 11: 478–484.
Park J, Lee MH, Lee HR, Park SH, Lee SH, Lee KE et al. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia. Bone Marrow Transplant 2003; 32: 889–895.
Vogelsang G, Bitton R, Piantadosi S, Altomonte V, Horn T, Jones R et al. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial. Bone Marrow Transplant 1999; 24: 637–640.
Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Altomonte V, Hess AD et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031–3035.
Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Altomonte V et al. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994; 12: 249–257.
Rappeport J, Mihm M, Reinherz E, Lopansri S, Parkman R . Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors. Lancet 1979; 8145: 717–720.
Geller RB, Esa AH, Beschorner WE, Frondoza CG, Santos GW, Hess AD . Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1989; 74: 1165–1171.
Bryson JS, Lake-Bullock H, Pflugh DL, Jennings CD, Stuart PM, Caywood BE et al. In vivo reactivity of T cell clones isolated from mice with syngeneic graft-versus-host disease. Transplantation 1995; 60: 171–178.
Hess AD, Bright EC, Thoburn C, Vogelsang GB, Jones RJ, Kennedy MJ . Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood 1997; 89: 2203–2209.
Hess AD, Fischer AC, Horwitz L, Bright EC, Laulis MK . Characterization of peripheral autoregulatory mechanisms that prevent development of cyclosporin-induced syngeneic graft-versus-host disease. J Immunol 1994; 153: 400–411.
Ruvolo P, Bright E, Kennedy MJ, Morris L, Fischer A, Vogelsang G et al. Cyclosporine-induced autologous graft versus host disease: assessment of cytolytic effector mechanisms and the V beta T-cell receptor repertoire. Transplant Proc 1995; 27: 1363–1365.
Miura Y, Thoburn CJ, Bright EC, Sommer M, Lefell S, Ueda M et al. Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD. Blood 2001; 98: 868–876.
Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI . Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000; 95: 3011–3019.
de Arriba F, Corral J, Ayala F, Heras I, Moraleda JM, Osma MM et al. Autoaggression syndrome resembling acute graft-versus-host disease grade IV after autologous peripheral blood stem cell transplantation for breast cancer. Bone Marrow Transplant 1999; 23: 621–624.
Carella AM, Gaozza E, Congiu A, Carlier P, Frassoni F, Valbonesi M et al. Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation in hematological malignancies. Ann Hematol 1991; 62: 156–159.
Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Santos GW . Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia. Leuk Lymphoma 1993; 11: 215–220.
Gaspari AA, Cheng SF, DiPersio JF, Rowe JM . Roquinimex-induced graft-versus-host reaction after autologous bone marrow transplantation. J Am Acad Dermatol 1995; 33: 711–717.
Redman BG, Chou TH, Zalupski M, Uberti J, Flaherty L, Dan M et al. Phase I trial of sequential cyclophosphamide, cyclosporin A, and interferon-alpha in patients with cancer: attempt to induce autologous graft-versus-host reaction to elicit an antitumor response. J Immunother Emphasis Tumor Immunol 1995; 18: 115–118.
Nakamura H, Nakao T, Ujiie H, Karasuno T, Teshima H, Komatsu K et al. Induction of autologous graft-versus-host disease after autologous peripheral blood stem cell transplantation. J Allergy Clin Immunol 1999; 103: S457–S461.
van der Wall E, Horn T, Bright E, Passos-Coehlo JL, Bond S, Clarke B et al. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. Br J Cancer 2000; 83: 1405–1411.
Miura Y, Ueda M, Zeng W, Wang H, Takani A, Yamazaki H et al. Induction of autologous graft-versus-host disease with cyclosporin A after peripheral blood stem cell transplantation: analysis of factors affecting induction. J Allergy Clin Immunol 2000; 106: S51–S57.
Streetly M, Kazmi M, Radia D, Hoyle C, Schey SA . Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation. Bone Marrow Transplant 2004; 33: 1131–1135.
Noga SJ, Horwitz L, Kim H, Laulis MK, Hess AD . Interferon-gamma potentiates the antitumor effect of cyclosporine-induced autoimmunity. J Hematother 1992; 1: 75–84.
Greiner J, Schmitt M, Li L, Giannopoulos K, Schmitt A, Dohner K et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109–4117.
Zenz T, Ritgen M, Dreger P, Krober A, Barth TF, Schlenk R et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 108: 2127–2130.
Ohsuga Y, Rowe JM, Liesveld J, Burns RP, Gaspari AA . Dermatologic changes associated with roquinimex immunotherapy after autologous bone marrow transplant. J Am Acad Dermatol 2000; 43: 437–441.
Hess AD, Thoburn CJ . Immune tolerance to self-major histocompatibility complex class II antigens after bone marrow transplantation: role of regulatory T cells. Biol Blood Marrow Transplant 2006; 12: 518–529.
Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057–1061.
Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN . Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200: 771–782.
Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623–3633.
Nemunaitis J . Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines 2005; 4: 259–274.
Messina G, Quartarone E, Console G, Cuzzola M, Iacopino O, Martino M et al. Systemic aspergillosis in a patient with non-Hodgkin's lymphoma developing acute graft-versus-host disease after autologous peripheral blood stem cell transplantation. Haematologica 2002; 87: ECR22.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kline, J., Subbiah, S., Lazarus, H. et al. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant 41, 505–513 (2008). https://doi.org/10.1038/sj.bmt.1705931
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705931
- Springer Nature Limited
Keywords
This article is cited by
-
Selective involution of thymic medulla by cyclosporine A with a decrease of mature thymic epithelia, XCR1+ dendritic cells, and epithelium-free areas containing Foxp3+ thymic regulatory T cells
Histochemistry and Cell Biology (2021)
-
Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge?
Bone Marrow Transplantation (2017)
-
Engraftment syndrome: double-edged sword of hematopoietic cell transplants
Bone Marrow Transplantation (2015)
-
Autologous GVHD?
Bone Marrow Transplantation (2014)
-
Reconstitution of regulatory T cells after autologous transplantation in multiple myeloma
International Journal of Hematology (2011)